Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Zydus Lifesciences Limited Press Release Jun 02 2025

· Issued by Zydus Lifesciences Limited via NSE India

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release announcing that it received tentative approval from the USFDA for Rifaximin Tablets, which are used to treat irritable bowel syndrome with diarrhoea in adults. The tablets will be manufactured at the company's facility in Ahmedabad.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases